ENDV
Endonovo Therapeutics, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 549,721 |
Stock Information
| Shares Outstanding | 1.81B |
| Total Debt | $7.06M |
| Revenue | $256K |
| Net Income | $-4.40M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $181K |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Sales | $256K |
| Income | $-4.40M |
| Book/sh | $-0.07 |
Financial Ratios
| Current Ratio | 0.00 |
Returns & Margins
| ROA | -144.27% |
| Gross Margin | 96.21% |
| Operating Margin | -31105.07% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/S | 0.71 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | nan |
| Shares Float | 255.51M |
| Volatility | 24.28 |
| Rel Volume | 0.32 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +100.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| Year | -50.00% |
| 3 Years | -99.24% |
| 5 Years | -99.67% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.00 | 100,010 |
| 2026-06-17 | $0.00 | 0 |
| 2026-06-16 | $0.00 | 0 |
| 2026-06-15 | $0.00 | 0 |
| 2026-06-12 | $0.00 | 0 |
| 2026-06-11 | $0.00 | 0 |
| 2026-06-10 | $0.00 | 1,016 |
| 2026-06-09 | $0.00 | 599,721 |
| 2026-06-08 | $0.00 | 0 |
| 2026-06-05 | $0.00 | 0 |
| 2026-06-04 | $0.00 | 300,000 |
| 2026-06-03 | $0.00 | 100,000 |
| 2026-06-02 | $0.00 | 170,000 |
| 2026-06-01 | $0.00 | 477,050 |
| 2026-05-29 | $0.00 | 2,500,800 |
| 2026-05-28 | $0.00 | 500,000 |
| 2026-05-27 | $0.00 | 1,494,000 |
| 2026-05-26 | $0.00 | 0 |
| 2026-05-22 | $0.00 | 0 |
| 2026-05-21 | $0.00 | 0 |
| 2026-05-20 | $0.00 | 0 |
| 2026-05-19 | $0.00 | 0 |
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ENDV.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,709 | $7,840 | $9,990 | $14,985 |
| Cost Of Revenue | $6,709 | $7,840 | $9,990 | $14,985 |
| Total Revenue | $10,043 | $140,242 | $135,355 | $73,105 |
| Operating Revenue | $10,043 | $140,242 | $135,355 | $73,105 |
| Expenses | ||||
| Interest Expense | $1,237,364 | $1,282,296 | $1,321,575 | $941,566 |
| Total Expenses | $1,569,976 | $3,059,686 | $3,399,695 | $2,299,652 |
| Net Non Operating Interest Income Expense | $-1,237,364 | $-1,282,296 | $-1,321,575 | $-941,566 |
| Interest Expense Non Operating | $1,237,364 | $1,282,296 | $1,321,575 | $941,566 |
| Operating Expense | $1,563,267 | $3,051,846 | $3,389,705 | $2,284,667 |
| Other Operating Expenses | $1,563,267 | $3,051,846 | $3,389,705 | $2,284,667 |
| Other Income Expense | - | $11,126,334 | $-13,888,920 | $63,219 |
| Other Non Operating Income Expenses | - | $-31,999 | $-225,268 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Net Interest Income | $-1,237,364 | $-1,282,296 | $-1,321,575 | $-941,566 |
| Normalized Income | $-2,797,297 | $-4,233,739 | $-4,811,183 | $-3,168,113 |
| Net Income From Continuing And Discontinued Operation | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Total Operating Income As Reported | $-1,559,933 | $-2,919,444 | $-3,264,340 | $-2,226,547 |
| Net Income Common Stockholders | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Net Income | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Net Income Including Noncontrolling Interests | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Net Income Continuous Operations | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Pretax Income | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Special Income Charges | $0 | $146,724 | $362,894 | $22,162 |
| Operating Income | $-1,559,933 | $-2,919,444 | $-3,264,340 | $-2,226,547 |
| Gross Profit | $3,334 | $132,402 | $125,365 | $58,120 |
| Per Share | ||||
| Diluted EPS | $0.00 | $0.01 | $-0.13 | $-0.05 |
| Basic EPS | $0.00 | $0.03 | $-0.13 | $-0.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-941,401 | $-2,304,531 | $-2,842,696 | $-1,578,055 |
| Total Unusual Items | $0 | $11,158,333 | $-13,663,652 | $63,219 |
| Total Unusual Items Excluding Goodwill | $0 | $11,158,333 | $-13,663,652 | $63,219 |
| Reconciled Depreciation | $618,532 | $646,912 | $646,912 | $648,492 |
| EBITDA (Bullshit earnings) | $-941,401 | $8,853,802 | $-16,506,348 | $-1,514,836 |
| EBIT | $-1,559,933 | $8,206,890 | $-17,153,260 | $-2,163,328 |
| Diluted Average Shares | $543,871,313 | $276,355,156 | $139,206,511 | $59,836,620 |
| Basic Average Shares | $543,871,313 | $276,355,156 | $139,206,511 | $59,836,620 |
| Diluted NI Availto Com Stockholders | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | - | $-146,724 | $-362,894 | $-22,162 |
| Gain On Sale Of Security | - | $11,011,609 | $-14,026,546 | $41,057 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-26,804,378 | $-24,726,471 | $-33,445,763 | $-17,686,680 |
| Total Assets | $17,719 | $638,086 | $1,281,266 | $2,007,211 |
| Total Non Current Assets | $0 | $618,531 | $1,265,444 | $1,912,356 |
| Goodwill And Other Intangible Assets | $0 | $618,531 | $1,265,444 | $1,912,356 |
| Current Assets | $17,719 | $19,554 | $15,822 | $94,855 |
| Other Current Assets | $17,716 | $17,716 | $15,724 | $7,975 |
| Receivables | $0 | $0 | $0 | $944 |
| Accounts Receivable | $0 | $0 | $0 | $944 |
| Cash Cash Equivalents And Short Term Investments | $3 | $1,838 | $98 | $85,936 |
| Cash And Cash Equivalents | $3 | $1,838 | $98 | $85,936 |
| Cash Financial | $3 | $1,838 | $98 | $85,936 |
| Other Intangible Assets | - | $618,531 | $1,265,444 | $1,912,356 |
| Allowance For Doubtful Accounts Receivable | - | $0 | $0 | $0 |
| Gross Accounts Receivable | - | $0 | $0 | $944 |
| Prepaid Assets | - | - | - | $7,975 |
| Debt | ||||
| Net Debt | $6,869,616 | $7,070,972 | $7,153,147 | $7,095,194 |
| Total Debt | $6,869,619 | $7,072,810 | $7,153,245 | $7,181,130 |
| Current Debt And Capital Lease Obligation | $6,869,619 | $7,072,810 | $7,153,245 | $7,181,130 |
| Current Debt | $6,869,619 | $7,072,810 | $7,153,245 | $7,181,130 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $26,822,097 | $24,746,026 | $33,461,585 | $17,781,535 |
| Total Non Current Liabilities Net Minority Interest | $79,824 | $79,824 | $79,825 | $79,825 |
| Other Non Current Liabilities | $79,824 | $79,824 | $79,825 | $79,825 |
| Current Liabilities | $26,742,273 | $24,666,202 | $33,381,760 | $17,701,710 |
| Other Current Liabilities | $6,336,686 | $6,336,686 | $17,359,064 | $3,442,297 |
| Current Deferred Liabilities | $4,266,904 | $5,417,112 | $4,442,606 | $3,891,361 |
| Current Notes Payable | $6,869,619 | $7,072,810 | $7,153,245 | $7,181,130 |
| Payables And Accrued Expenses | $9,269,064 | $5,839,594 | $4,426,845 | $3,186,922 |
| Interest Payable | $5,839,253 | $4,756,956 | $3,542,650 | $2,528,459 |
| Payables | $3,429,811 | $1,082,638 | $884,195 | $658,463 |
| Accounts Payable | $3,429,811 | $1,082,638 | $884,195 | $658,463 |
| Tradeand Other Payables Non Current | - | - | - | $79,825 |
| Equity | ||||
| Common Stock Equity | $-26,804,404 | $-24,107,966 | $-32,180,345 | $-15,774,350 |
| Preferred Stock Equity | $26 | $26 | $26 | $26 |
| Total Equity Gross Minority Interest | $-26,804,378 | $-24,107,940 | $-32,180,319 | $-15,774,324 |
| Stockholders Equity | $-26,804,378 | $-24,107,940 | $-32,180,319 | $-15,774,324 |
| Other Equity Interest | $-1,570 | $-1,570 | $-1,570 | $-1,570 |
| Retained Earnings | $-71,031,284 | $-68,233,987 | $-75,119,183 | $-56,443,416 |
| Other | ||||
| Ordinary Shares Number | $543,871,313 | $318,751,597 | $213,227,538 | $74,498,761 |
| Share Issued | $543,871,313 | $318,751,597 | $213,227,538 | $74,498,761 |
| Tangible Book Value | $-26,804,404 | $-24,726,497 | $-33,445,789 | $-17,686,706 |
| Invested Capital | $-19,934,785 | $-17,035,156 | $-25,027,100 | $-8,593,220 |
| Working Capital | $-26,724,554 | $-24,646,648 | $-33,365,938 | $-17,606,855 |
| Total Capitalization | $-26,804,378 | $-24,107,940 | $-32,180,319 | $-15,774,324 |
| Additional Paid In Capital | $44,174,080 | $44,095,049 | $42,919,086 | $40,663,187 |
| Capital Stock | $54,396 | $32,568 | $21,348 | $7,475 |
| Common Stock | $54,370 | $32,542 | $21,322 | $7,449 |
| Preferred Stock | $26 | $26 | $26 | $26 |
| Current Accrued Expenses | $5,839,253 | $4,756,956 | $3,542,650 | $2,528,459 |
| Net PPE | - | - | - | $0 |
| Accumulated Depreciation | - | - | - | $0 |
| Gross PPE | - | - | - | $0 |
| Machinery Furniture Equipment | - | - | - | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $100,487 | $121,870 | $-678,838 | $-986,584 |
| Operating Activities | ||||
| Operating Cash Flow | $100,487 | $121,870 | $-678,838 | $-986,584 |
| Cash Flow From Continuing Operating Activities | $100,487 | $121,870 | $-1,217,620 | $-986,584 |
| Operating Gains Losses | - | $-11,022,378 | $13,663,652 | $-63,219 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | - | $0 |
| Cash Flow From Continuing Investing Activities | - | - | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $97,859 | $10,720 | $142,000 | $126,000 |
| Financing Cash Flow | $-105,332 | $-120,130 | $593,000 | $1,059,100 |
| Cash Flow From Continuing Financing Activities | $-105,332 | $-120,130 | $593,000 | $1,059,100 |
| Net Common Stock Issuance | $97,859 | $10,720 | $142,000 | $126,000 |
| Common Stock Issuance | $97,859 | $10,720 | $142,000 | $126,000 |
| Net Other Financing Charges | - | $-9,800 | $-14,000 | $-16,900 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-203,191 | $-121,050 | - | - |
| End Cash Position | $3 | $1,838 | $98 | $85,936 |
| Beginning Cash Position | $1,838 | $98 | $85,936 | $13,420 |
| Changes In Cash | $-1,835 | $1,740 | $-85,838 | $72,516 |
| Net Issuance Payments Of Debt | $-203,191 | $-121,050 | $465,000 | $950,000 |
| Net Short Term Debt Issuance | $-203,191 | $-121,050 | $465,000 | - |
| Short Term Debt Payments | $-203,191 | $-121,050 | - | - |
| Change In Working Capital | $2,279,252 | $1,708,315 | $1,470,498 | $1,222,621 |
| Change In Other Working Capital | $-1,150,218 | $974,506 | $551,245 | $507,244 |
| Change In Payables And Accrued Expense | $3,429,470 | $735,802 | $927,003 | $691,529 |
| Change In Accrued Expense | $1,082,297 | $1,214,306 | $1,196,394 | $733,999 |
| Change In Interest Payable | $1,082,297 | $1,214,306 | $1,196,394 | $733,999 |
| Change In Payable | $2,347,173 | $-478,504 | $-269,391 | $-42,470 |
| Change In Account Payable | $2,347,173 | $-478,504 | $-269,391 | $-42,470 |
| Change In Prepaid Assets | $0 | $-1,993 | $-7,750 | $23,850 |
| Stock Based Compensation | $0 | $686,747 | $45,000 | $0 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | - | - |
| Asset Impairment Charge | $0 | $0 | $944 | $0 |
| Depreciation Amortization Depletion | $618,532 | $646,912 | $646,912 | $648,492 |
| Depreciation And Amortization | $618,532 | $646,912 | $646,912 | $648,492 |
| Net Income From Continuing Operations | $-2,797,297 | $6,924,594 | $-18,474,835 | $-3,104,894 |
| Other Non Cash Items | - | $1,177,680 | $1,968,991 | $310,416 |
| Gain Loss On Investment Securities | - | $-11,022,378 | $14,026,546 | $-41,057 |
| Issuance Of Debt | - | - | $465,000 | $950,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Short Term Debt Issuance | - | - | $465,000 | - |
| Net Long Term Debt Issuance | - | - | $465,000 | $950,000 |
| Long Term Debt Issuance | - | - | $465,000 | $950,000 |
| Change In Receivables | - | - | $0 | $-2 |
| Changes In Account Receivables | - | - | $0 | $-2 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
Fetched: 2026-02-02